CytRx Reports Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas
January 08, 2014 at 08:35 AM EST
CytRx (NASDAQ: CYTR ) today reported positive results from additional statistical analyses that further support the previously announced highly positive top-line efficacy results from a
